跳至主要内容
临床试验/CTRI/2023/08/056077
CTRI/2023/08/056077招募中Unknown

Real World Evidence on safety and effectiveness of single inhaler triple-therapy(glycopyrrolate/formoterol fumarate/budesonide) in patients with COPD - NI

Zydus Healthcare Ltd. India0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Eligible for single inhaler triple therapy (LABA + LAMA + ICS) as per clinician’s discretion
  • Gives signed written informed consent to participate.
  • For Female patients
  • A female is eligible to enter and participate in the study if she is of non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal)
  • For females with childbearing potential, who agrees for contraception throughout - from Visit 1 (Screening) till 1 month after the final visit)

排除标准

  • 未提供

研究者

发起方
Zydus Healthcare Ltd. India

相似试验